Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.
Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser
Mazti Asmae, El Koubaiti ghizlane, El Idrissi Mohamed, El Ibrahimi Abdelhalim, EL Maaroufi Mustapha, El Fakir Samira, Arifi Samia, Bouhafa Touria, Mrini Abdelmajid and Chbani Laila
Introduction: Soft tissue sarcomas are malignant tumors that require management in specialized centers. The aim of our study is to evaluate the benefit of the multidisciplinary meeting (RCM) on the management of these tumors.
Materials and methods: It is a prospective study, which is conducted in the HASSAN II University Hospital Center in Fez. This research project has lasted for a period of 28 months.
Results: ninety-seven (97) cases were selected, the average age was 52 years. The lower limb is the most frequent site (77%) with deep localization in 92.8% of cases. Eighty-two patients (88%) have had a prior biopsy. Seventy-three patients (75.3%) have received MRI before surgery. Fifty-six patients were operated, with R0 resection in 34 patients, R1 in 16 patients and R2 in 6 patients. Liposarcomas were the most frequent (26.5%), followed by synovialosarcomas (14.4%), leiomyosarcomas (10.3%) and undifferentiated pleomorphic sarcomas (10.3%). Neoadjuvant chemotherapy was indicated in 30 patients. Adjuvant chemotherapy or radiotherapy was indicated in 22 patients. The overall survival rate was 15.19 months, with a significant improvement in survival in patients with multidisciplinary management.
Conclusion: The presented data are similar to the literature one with respect to the interest of multidisciplinary management of soft tissue sarcomas, specifically on the prognosis and survival of patients.